SG11202105358RA - Gaboxadol for reducing risk of suicide and rapid relief of depression - Google Patents

Gaboxadol for reducing risk of suicide and rapid relief of depression

Info

Publication number
SG11202105358RA
SG11202105358RA SG11202105358RA SG11202105358RA SG11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA SG 11202105358R A SG11202105358R A SG 11202105358RA
Authority
SG
Singapore
Prior art keywords
gaboxadol
suicide
depression
reducing risk
rapid relief
Prior art date
Application number
SG11202105358RA
Other languages
English (en)
Inventor
Pavel Osten
Kristin Baldwin
Original Assignee
Certego Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Certego Therapeutics filed Critical Certego Therapeutics
Publication of SG11202105358RA publication Critical patent/SG11202105358RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202105358RA 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression SG11202105358RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770287P 2018-11-21 2018-11-21
PCT/US2019/062554 WO2020106927A1 (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Publications (1)

Publication Number Publication Date
SG11202105358RA true SG11202105358RA (en) 2021-06-29

Family

ID=70728606

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105358RA SG11202105358RA (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Country Status (13)

Country Link
US (3) US20220008398A1 (https=)
EP (1) EP3883566A4 (https=)
JP (1) JP2022514194A (https=)
KR (1) KR20210110585A (https=)
CN (1) CN113395962A (https=)
AU (1) AU2019384157A1 (https=)
BR (1) BR112021009944A2 (https=)
CA (1) CA3120856A1 (https=)
GB (1) GB2594616A (https=)
IL (1) IL283311A (https=)
MX (1) MX2021005992A (https=)
SG (1) SG11202105358RA (https=)
WO (1) WO2020106927A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
JP2024020037A (ja) * 2022-08-01 2024-02-14 学校法人順天堂 痛みと痒みのバイオマーカー

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
CL2004001603A1 (es) 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
TW200509918A (en) 2003-06-25 2005-03-16 Lundbeck & Co As H Treatment of depression and other affective disorders
TW200501951A (en) 2003-06-25 2005-01-16 Lundbeck & Co As H Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
ZA200607427B (en) 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20080159958A1 (en) 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
GB0810063D0 (en) 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
US11083732B2 (en) 2014-03-31 2021-08-10 University Of Maryland, Baltimore Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants
WO2015171547A1 (en) 2014-05-05 2015-11-12 Ovid Therapeutics Inc. Methods of treating cognitive impairment associated with neurodegenerative disorders
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
US20170304358A1 (en) 2014-10-06 2017-10-26 Seyyed Nassir GHAEMI Primary and secondary prevention of dementias and suicide with trace dose lithium
LT3274331T (lt) 2015-03-24 2020-04-10 H. Lundbeck A/S 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas
WO2016176609A1 (en) 2015-04-30 2016-11-03 Ovid Therapeutics Inc Methods of treating prader-willi syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
AR105378A1 (es) 2015-07-17 2017-09-27 Ovid Therapeutics Inc Métodos de tratamiento de trastornos del desarrollo con gaboxadol
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
AR105670A1 (es) 2015-08-11 2017-10-25 Ovid Therapeutics Inc Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
JP6857647B2 (ja) 2015-08-11 2021-04-14 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20170119704A1 (en) 2015-10-13 2017-05-04 Ovid Therapeutics Inc. Treatment of cognitive impairment
WO2017205606A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10737984B2 (en) 2016-11-30 2020-08-11 Hrl Laboratories, Llc Formulations and methods for 3D printing of ceramic matrix composites
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN110621318A (zh) 2017-03-15 2019-12-27 奥维德医疗公司 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2018222957A1 (en) 2017-06-01 2018-12-06 Ovid Therapeutics Inc. Treatment of developmental disorders with imidazolone derivatives
WO2019006161A1 (en) 2017-06-28 2019-01-03 Ovid Therapeutics Inc. TREATMENT OF DEVELOPMENT SYNDROMES
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
AU2018320849A1 (en) 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
JP2020533415A (ja) 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ナルコレプシーの処置におけるガボキサドールの使用
CN107595850A (zh) 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种有效提高睡眠质量的药物组合物及其用途
JP2021521103A (ja) 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール

Also Published As

Publication number Publication date
GB202108720D0 (en) 2021-08-04
US20200155522A1 (en) 2020-05-21
JP2022514194A (ja) 2022-02-10
KR20210110585A (ko) 2021-09-08
US20220054461A1 (en) 2022-02-24
AU2019384157A1 (en) 2021-06-17
US20220008398A1 (en) 2022-01-13
CA3120856A1 (en) 2020-05-28
CN113395962A (zh) 2021-09-14
EP3883566A1 (en) 2021-09-29
BR112021009944A2 (pt) 2021-08-17
GB2594616A (en) 2021-11-03
WO2020106927A1 (en) 2020-05-28
IL283311A (en) 2021-07-29
US11123332B2 (en) 2021-09-21
MX2021005992A (es) 2021-09-14
EP3883566A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
IL283311A (en) Goxadol for reducing the risk of suicide and rapid relief from depression
EP3852533B8 (en) Pyridazinones and methods of use thereof
EP3810617A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3649240A4 (en) RNAI ALPHA-ENaC GENE EXPRESSION INHIBITION AGENTS AND METHODS OF USE
EP3376778B8 (en) Microphone and method of testing a microphone
PL3528811T3 (pl) Wortioksetyna i inhibitory mao do leczenia depresji
EP3927344A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION
HK40060802A (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
AU2017254113B2 (en) Implants and methods for treatments of pelvic conditions
EP3755361A4 (en) NASH TREATMENT METHODS AND COMPOSITIONS THEREFOR
HK40065394A (en) Methods and compositions of treating an ophthalmic condition
HK40053358A (en) Anellosomes and methods of use
HK40078033A (en) Il-2 orthologs and methods of use
HK40015210A (en) Cyclin g1 inhibitors and related methods of treating cancer
HK40069053A (en) Kcnt1 inhibitors and methods of use
HK40073844A (en) Vegf mini-traps and methods of use thereof
HK40055592A (en) Catabodies and methods of use thereof
HK40015875A (en) Compositions and methods for prevention and treatment of hearing loss
HK40048203A (en) Ssao inhibitors and uses thereof
AU2018902563A0 (en) Isolation of metals and other elements
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof
AU2019902520A0 (en) Isolation of metals and other elements
HK40054921A (en) Compositions and methods for treating cellulite
HK40043593A (en) Imidazodiazepinediones and methods of use thereof
HK40030966A (zh) 用於抑制α-ENAC表达的RNAI剂及使用方法